SynCore Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.58%

SynCore Biotechnology Co Ltd (4192) has an Asset Resilience Ratio of 2.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of SynCore Biotechnology Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

NT$7.04 Million
≈ $221.67K USD Cash + Short-term Investments

Total Assets

NT$272.85 Million
≈ $8.60 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how SynCore Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See 4192 book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down SynCore Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of SynCore Biotechnology Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$7.04 Million 2.58%
Total Liquid Assets NT$7.04 Million 2.58%

Asset Resilience Insights

  • Limited Liquidity: SynCore Biotechnology Co Ltd maintains only 2.58% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

SynCore Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare SynCore Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for SynCore Biotechnology Co Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for SynCore Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.19% NT$6.96 Million
≈ $219.15K
NT$317.80 Million
≈ $10.01 Million
+0.43pp
2023-12-31 1.76% NT$6.66 Million
≈ $209.83K
NT$378.36 Million
≈ $11.92 Million
+0.23pp
2022-12-31 1.53% NT$6.66 Million
≈ $209.83K
NT$436.65 Million
≈ $13.76 Million
+0.72pp
2021-12-31 0.81% NT$6.66 Million
≈ $209.83K
NT$824.44 Million
≈ $25.97 Million
+0.08pp
2020-12-31 0.73% NT$6.66 Million
≈ $209.83K
NT$913.99 Million
≈ $28.80 Million
-0.14pp
2019-12-31 0.87% NT$6.66 Million
≈ $209.83K
NT$763.88 Million
≈ $24.07 Million
+0.04pp
2018-12-31 0.83% NT$6.66 Million
≈ $209.83K
NT$804.80 Million
≈ $25.36 Million
+0.04pp
2017-12-31 0.79% NT$6.66 Million
≈ $209.83K
NT$845.89 Million
≈ $26.65 Million
+0.19pp
2016-12-31 0.60% NT$6.66 Million
≈ $209.83K
NT$1.11 Billion
≈ $35.12 Million
-0.05pp
2015-12-31 0.65% NT$6.63 Million
≈ $208.82K
NT$1.03 Billion
≈ $32.36 Million
--
pp = percentage points

About SynCore Biotechnology Co Ltd

TWO:4192 Taiwan Biotechnology
Market Cap
$21.71 Million
NT$689.23 Million TWD
Market Cap Rank
#24789 Global
#1552 in Taiwan
Share Price
NT$19.60
Change (1 day)
-1.75%
52-Week Range
NT$19.55 - NT$30.35
All Time High
NT$537.12
About

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more